Psychol Bull 1979, 86: 638–641.CrossRef 26. Vieira JO, da Silva ID, Higo PE, Nogueira-de-Souza NC, Gebrim LH: Study of p53 codon 72 polymorphism in patients with breast cancer. Eur J Gynaecol Oncol 2008, 29: 364–367.PubMed 27. Bonafé M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C: Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer

patients. Clin Cancer Res 2003, 9: 4860–4864.PubMed 28. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y: p53 Codon 72 polymorphism predicts the pathologic response to neohttps://www.selleckchem.com/products/BafilomycinA1.html adjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005, 11: 7328–7333.CrossRefPubMed 29. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K: Evidence for selective expression VX-680 cost of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 2005, 14: 2245–2252.CrossRefPubMed 30. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y: Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007, 9: R34.CrossRefPubMed

31. Hamaguchi M, Nishio M, Toyama T, SBE-��-CD purchase Sugiura H, Kondo N, Fujii Y, Yamashita H: Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers. Jpn J Clin Oncol 2008, 38: 734–742.CrossRefPubMed 32. Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, Fabbri F, Ulivi P, Brigliadori G, Amadori D, Bonafe M: Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol 2008, 29: 145–151.CrossRefPubMed 33. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy

K: MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 2008, 29: 754–761.CrossRefPubMed medroxyprogesterone 34. Kyndi M, Alsner J, Hansen LL, Sørensen FB, Overgaard J: LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 2006, 45: 602–609.CrossRefPubMed 35. Ogretmen B, Safa AR: Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997, 14: 499–506.CrossRefPubMed 36. Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL: The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.